Babis Andreadis

Babis Andreadis is a Professor of Medicine at the University of California, San Francisco (UCSF) School of Medicine specializing in hematology and oncology. He serves as Director of the Baszucki Lymphoma Therapeutic Initiative and hematology clinical research co-chair at UCSF, where he treats patients with hematologic malignancies including Hodgkin's and non-Hodgkin's lymphoma, leukemia, and multiple myeloma.

His educational background includes:

• BA, Cum Laude, Biochemistry, Oberlin College (1993)
• MD, Medicine, College of Physicians & Surgeons, Columbia University (1998)
• Residency, Internal Medicine, Columbia-Presbyterian Medical Center (2001)
• Fellowship, Hematology/Oncology, Hospital of the University of Pennsylvania (2004)
• MSCE, Pharmacogenetics, University of Pennsylvania (2005)

Dr. Andreadis's research focuses on identifying genetic determinants of response to and toxicity from cancer therapy. His work integrates clinical practice with genetic pharmacoepidemiology, collaborating with institutions including BMT-CTN and ALLIANCE to improve outcomes for patients with blood cancers through personalized medicine approaches.

His numerous honors include:

• Bay Area Man of the Year, Leukemia & Lymphoma Society (2015)
• Marc A. Shuman Mentoring Award (2013)
• Hematology Teaching Award (2012)
• Alpha Omega Alpha membership (1997)

As an educator, Dr. Andreadis has received multiple teaching awards at UCSF and maintains a 5.0/5.0 patient satisfaction rating based on 275 reviews, with patients consistently praising his expertise, thoroughness, and compassionate care.

He leads the Hematology, Blood & Marrow Transplant, and Cellular Therapy (HBC) Program at UCSF Helen Diller Family Comprehensive Cancer Center, where he applies his dual expertise in clinical hematology/oncology and pharmacogenetics to advance patient care and research in hematologic malignancies.